About 81% of people with newly diagnosed multiple myeloma who received the antibody drug daratumumab along with standard therapy were alive without their cancer worsening six years later, compared with 56% of those who got standard therapy alone. The long-term results from the PERSEUS trial were presented at the International Myeloma Society's annual meeting in Glasgow, Scotland, held Sept. 23 to 26, OncLive reported.
Multiple myeloma is a cancer of plasma cells in the bone marrow. It is not considered curable, and most patients eventually relapse, so the length of a first remission shapes years of a person's life. For patients and families weighing a first treatment plan, six-year data offer a longer view than most trials provide.
